Shares of Kenvue fell more than 10% on Friday after a report that Health and Human Services Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women. 

HHS will release the report that could draw that link this month, the Wall Street Journal reported on Friday.

That report will also suggest a medicine derived from folate – a water-soluble vitamin – can be used to treat symptoms of the developmental disorder in some people, according to the Journal.

In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.

The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.

This is breaking news. Please refresh for updates.